title: The effects of proresolution of ellagic acid in an experimental model of allergic airway inflammation.
abstract: Asthma is a disease of airway inflammation characterized by airway hyperresponsiveness, eosinophilic inflammation, and hypersecretion of mucus. Ellagic acid, a compound derived from medicinal plants and fruits, has shown anti-inflammatory activity in several experimental disease models. We used the classical experimental model, in BALB/c mice, of sensibilization with ovalbumin to determine the effect of ellagic acid (10 mg/kg; oral route) in the resolution of allergic airways response. Dexamethasone (1 mg/kg; subcutaneous route) was used as a positive control. The control group consisted of nonimmunized mice that received challenge with ovalbumin. Ellagic acid and dexamethasone or vehicle (water) were administered before or after intranasal allergen challenge. Ellagic acid accelerated the resolution of airways inflammation by decreasing total leukocytes and eosinophils numbers in the bronchoalveolar lavage fluid (BALF), the mucus production and lung inflammation in part by reducing IL-5 concentration, eosinophil peroxidase (EPO) activity, and P-selectin expression, but not activator protein 1 (AP-1) and nuclear factor kappa B (NF-κB) pathways. In addition, ellagic acid enhanced alveolar macrophage phagocytosis of IgG-OVA-coated beads ex vivo, a new proresolving mechanism for the clearance of allergen from the airways. Together, these findings identify ellagic acid as a potential therapeutic agent for accelerating the resolution of allergic airways inflammation.
authors.affiliation: Laboratório de ImunoFarmacologia Experimental (LIFE), Departamento de Clínica Médica, Instituto de Ciências da Saúde, Universidade Federal do Triângulo Mineiro (UFTM), Rua Manoel Carlos 162, 38025-380 Uberaba, MG, Brazil.
authors.forename: Claudiney de Freitas
authors.initials: Cde F
authors.lastname: Alves
authors.affiliation: Laboratório de ImunoFarmacologia Experimental (LIFE), Departamento de Clínica Médica, Instituto de Ciências da Saúde, Universidade Federal do Triângulo Mineiro (UFTM), Rua Manoel Carlos 162, 38025-380 Uberaba, MG, Brazil.
authors.forename: Giovanna Natalia
authors.initials: GN
authors.lastname: Angeli
authors.affiliation: Laboratório de ImunoFarmacologia Experimental (LIFE), Departamento de Clínica Médica, Instituto de Ciências da Saúde, Universidade Federal do Triângulo Mineiro (UFTM), Rua Manoel Carlos 162, 38025-380 Uberaba, MG, Brazil.
authors.forename: Daniely Cornélio
authors.initials: DC
authors.lastname: Favarin
authors.affiliation: Departamento de Farmacologia, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
authors.forename: Edinéia Lemos
authors.initials: EL
authors.lastname: de Andrade
authors.affiliation: Laboratório de ImunoFarmacologia Experimental (LIFE), Departamento de Clínica Médica, Instituto de Ciências da Saúde, Universidade Federal do Triângulo Mineiro (UFTM), Rua Manoel Carlos 162, 38025-380 Uberaba, MG, Brazil.
authors.forename: Javier Emilio Lazo
authors.initials: JE
authors.lastname: Chica
authors.affiliation: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.
authors.forename: Lúcia Helena
authors.initials: LH
authors.lastname: Faccioli
authors.affiliation: Laboratório de ImunoFarmacologia Experimental (LIFE), Departamento de Clínica Médica, Instituto de Ciências da Saúde, Universidade Federal do Triângulo Mineiro (UFTM), Rua Manoel Carlos 162, 38025-380 Uberaba, MG, Brazil.
authors.forename: Paulo Roberto
authors.initials: PR
authors.lastname: da Silva
authors.affiliation: Laboratório de ImunoFarmacologia Experimental (LIFE), Departamento de Clínica Médica, Instituto de Ciências da Saúde, Universidade Federal do Triângulo Mineiro (UFTM), Rua Manoel Carlos 162, 38025-380 Uberaba, MG, Brazil.
authors.forename: Alexandre de Paula
authors.initials: Ade P
authors.lastname: Rogerio
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D004610:Ellagic Acid / Q000627:therapeutic use*; D005260:Female; D015848:Interleukin-5 / Q000032:analysis; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology; D008264:Macrophages / Q000276:immunology; D008679:Metaplasia; D051379:Mice; D008807:Mice, Inbred BALB C; D016328:NF-kappa B / Q000032:analysis; D019007:P-Selectin / Q000032:analysis; D010587:Phagocytosis / Q000187:drug effects; D018808:Transcription Factor AP-1 / Q000032:analysis
chemical_list: D015848:Interleukin-5; D016328:NF-kappa B; D019007:P-Selectin; D018808:Transcription Factor AP-1; D004610:Ellagic Acid